Pharma Blog Watch

Obesity Drug Studies (QDIS Blog)
In response to commentary appearing in a recent issue of The Lancet about a need for more long-term data on obesity drugs, including Xenical (orlistat), Meridia (sibutramine) and Acomplia (rimonabant), Ed Vawter writes, "I tend to agree, especially since they all seem to have the potential for serious side effects which show up even with just short-term use. As I have said here many times, they risk and reward need to be weighed for the use of any drug."

"Long-term safety data will likely be one of the primary topics for FDA reform this year from the Democrats in Congress, especially in the House of Representatives."